Skip to main content
. 2024 Apr 24;18(2):101347. doi: 10.1016/j.jcmgh.2024.04.004

Figure 3.

Figure 3

Telocytes show altered distribution near the expanding proliferative zone in DMP-777-treated mouse stomach. (A) Immunofluorescence staining of Ki67 (white), FOXL1 (red), PDGFRα (green), and DAPI (blue) on DMP-777-treated stomach tissue. As DMP-777 treatment duration increased, the proliferative cell zone expanded, and FOXL1+/PDGFRα+ telocytes extended toward the base. Scale bar: 100 μm and 50 μm for enlarged. (B) Quantification of telocyte count. The number of FOXL1+/PDGFRα+/DAPI+ telocytes increased in the stomach following treatment with DMP-777. Data presented as mean ± standard deviation (n = 4, except for DMP-777 3 Days, n = 3). ∗P < .05; ∗∗∗∗P < .0001. Dunnett multiple comparisons test; 1-way analysis of variance (F (3, 11) = 27.28; P < .0001). (C) Quantification of telocyte distribution within the gland. The distribution histograms display relative positions of FOXL1+/PDGFRα+/DAPI+ telocytes along the height of the gland. The y-axis represents the relative height of the corpus gland, divided into 10% increments (1 = top and 0 = base). The x-axis represents the percentage of telocytes in each region. Extended treatment with DMP-777 reduced telocyte distribution at the top and increased presence in the mid and base regions of the gland. Data presented as mean ± standard deviation (n = 4, except for DMP-777 3 Days, n = 3). ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. Dunnett multiple comparisons test; 2-way analysis of variance for interaction (F (27, 99) = 15.47; P < .0001).